FDA panel backs second RSV vaccine for older Americans
Mar 02, 2023
In a two-part vote, the panel voted 10-to-2 in favor of the vaccine’s safety and unanimously on the shot’s effectiveness.
FDA panel backs Pfizer RSV vaccine for older Americans
Mar 01, 2023
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86%.
Providers to receive $250,000 for COVID-19 vaccine clinics
By
Kimberly Bonvissuto
Feb 21, 2023
LeadingAge will distribute more than $250,000 in grants to help its members host COVID-19 vaccination clinics to increase vaccination uptake among staff members, residents, family and community members.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
Moderna will offer free COVID-19 shots to uninsured after PHE ends
Feb 16, 2023
Moderna faces pressure since the US government subsidized its vaccine development.
Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors
Feb 16, 2023
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
COVID-19 vaccine protection lasts at least six months after second dose
Feb 07, 2023
Vaccine effectiveness against death was lower for patients aged 80 years and older.
COVID-19 vaccine primary series coverage 76 percent in adults 60 years and older
Feb 06, 2023
Primary series coverage by the end of 2022 was below the 100% target set for at-risk populations.
Republicans coming again for healthcare worker vaccine mandate
By
Jessica R. Towhey
Jan 31, 2023
The Republican-controlled US House of Representatives is expected to vote on two bills today that would have significant effects for long-term care providers.
Booster cuts COVID-19-related mortality in adults with chronic conditions
Jan 30, 2023
The findings “support the recent focus on older people and those with chronic conditions for future booster doses of SARS-CoV-2 vaccines beyond the first booster,” the authors write.